Cymabay Therapeu Analysis
| CBAYDelisted Stock | USD 11.83 0.27 2.34% |
Cymabay Therapeu is overvalued with Real Value of 9.13 and Hype Value of 11.83. The main objective of Cymabay Therapeu delisted stock analysis is to determine its intrinsic value, which is an estimate of what Cymabay Therapeu is worth, separate from its market price. There are two main types of Cymabay Therapeu's stock analysis: fundamental analysis and technical analysis.
The Cymabay Therapeu stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Cymabay Therapeu is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Cymabay Stock trading window is adjusted to America/New York timezone.
Cymabay |
Cymabay Stock Analysis Notes
About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.99. Cymabay Therapeu had not issued any dividends in recent years. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. Cymabay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people. For more info on Cymabay Therapeu please contact the company at 510 293 8800 or go to https://www.cymabay.com.Cymabay Therapeu Investment Alerts
| Cymabay Therapeu is not yet fully synchronised with the market data | |
| Cymabay Therapeu has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 31.07 M. Net Loss for the year was (105.37 M) with loss before overhead, payroll, taxes, and interest of (41.63 M). | |
| Cymabay Therapeu currently holds about 153.42 M in cash with (72.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies |
Cymabay Therapeu Upcoming and Recent Events
Earnings reports are used by Cymabay Therapeu to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Cymabay Therapeu Thematic Classifications
In addition to having Cymabay Therapeu stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Disruptive TechnologiesFirms and ETFs that are involved or betting on industries or trends that are projected to experience exponential growth |
Cymabay Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.73 B.Cymabay Therapeu Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cymabay Therapeu insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cymabay Therapeu's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cymabay Therapeu insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Robert Wills over six months ago Disposition of 49245 shares by Robert Wills of Cymabay Therapeu at 4.05 subject to Rule 16b-3 | ||
Paul Quinlan over six months ago Disposition of 41824 shares by Paul Quinlan of Cymabay Therapeu at 7.89 subject to Rule 16b-3 | ||
Sujal Shah over six months ago Acquisition by Sujal Shah of 14625 shares of Cymabay Therapeu at 1.06 subject to Rule 16b-3 | ||
Wiggans Thomas G over six months ago Acquisition by Wiggans Thomas G of 14010 shares of Cymabay Therapeu subject to Rule 16b-3 | ||
Stuart Lewis J over a year ago Acquisition by Stuart Lewis J of 215000 shares of Cymabay Therapeu subject to Rule 16b-3 |
Cymabay Therapeu Outstanding Bonds
Cymabay Therapeu issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cymabay Therapeu uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cymabay bonds can be classified according to their maturity, which is the date when Cymabay Therapeu has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Cymabay Therapeu Predictive Daily Indicators
Cymabay Therapeu intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cymabay Therapeu stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Cymabay Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Cymabay Therapeu prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cymabay shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Cymabay Therapeu. By using and applying Cymabay Stock analysis, traders can create a robust methodology for identifying Cymabay entry and exit points for their positions.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. Cymabay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Cymabay Therapeu to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Cymabay Stock
If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |